William Blair & Company
SLN

William Blair & Company’s Silence Therapeutics SLN Stock Holding History

William Blair & Company’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,000
Closed -$364K – 1879
2024
Q3 		$364K Sell
20,000
-5,432
-21% -$101K ﹤0.01% 1221
2024
Q2 		$483K Hold
25,432
– – ﹤0.01% 1106
2024
Q1 		$549K Sell
25,432
-116
-0.5% -$2.52K ﹤0.01% 1061
2023
Q4 		$444K Sell
25,548
-13,438
-34% -$151K ﹤0.01% 1103
2023
Q3 		$383K Hold
38,986
– – ﹤0.01% 1137
2023
Q2 		$214K Sell
38,986
-2,277
-6% -$13.7K ﹤0.01% 1387
2023
Q1 		$256K Sell
41,263
-624
-1% -$7.36K ﹤0.01% 1304
2022
Q4 		$639K Hold
41,887
– – ﹤0.01% 966
2022
Q3 		$420K Sell
41,887
-9,288
-18% -$97.7K ﹤0.01% 1107
2022
Q2 		$606K Sell
51,175
-4,950
-9% -$60.1K ﹤0.01% 1004
2022
Q1 		$1.07M Buy
56,125
+99
+0.2% +$1.97K ﹤0.01% 901
2021
Q4 		$1.34M Buy
56,026
+11,582
+26% +$268K ﹤0.01% 850
2021
Q3 		$911K Buy
+44,444
New +$1.06M ﹤0.01% 967

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

William Blair & Company's SLN Position: Q4 2024 in Review

William Blair & Company sold out of Silence Therapeutics (SLN) in Q4 2024, closing a stake of 20,000 shares — an estimated $364K sold.

William Blair & Company first reported a position in SLN in Q3 2021 and held it in 13 quarters. The position peaked at $1.34M in Q4 2021. 65 funds tracked by Wall St. Rank hold SLN as of Q4 2024.

  • William Blair & Company reported no remaining Silence Therapeutics position as of Q4 2024 after selling out during the quarter.
  • William Blair & Company sold 20,000 Silence Therapeutics shares in Q4 2024, an estimated $364K.
  • William Blair & Company first reported a position in Silence Therapeutics in Q3 2021 and held it in 13 quarters.
  • William Blair & Company's Silence Therapeutics position peaked at $1.34M in Q4 2021.
  • 65 funds tracked by Wall St. Rank held Silence Therapeutics as of Q4 2024.

Based on William Blair & Company's 13F filing for Q4 2024, filed 12 Feb 2025.